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SUMMARY
Ocular disease is the commonest disabling consequence of toxoplasma infection. Incidence and
lifetime risk of ocular symptoms were determined by ascertaining aﬀected patients in a
population-based, active reporting study involving ophthalmologists serving a population of 7±4
million. Eighty-seven symptomatic episodes were attributed to toxoplasma infection. Bilateral
visual acuity of 6}12 or less was found in seven episodes (8%) and was likely to have been
transient in most cases. Black people born in West Africa had a 100-fold higher incidence of
symptoms than white people born in Britain. Only two patients reported symptoms before 10
years of age. The estimated lifetime risk of symptoms in British born individuals (52% of all
episodes) was 18}100000 (95% con®dence interval: 10±8±25±2). The low risk and mild
symptoms in an unscreened British population indicate limited potential bene®ts of prenatal or
postnatal screening. The late age at presentation suggests a mixed aetiology of postnatally
acquired and congenital infection for which primary prevention may be appropriate,
particularly among West Africans.
INTRODUCTION
In many European countries, considerable resources
(at least $48 million per year in France alone, 1992
prices [1]) are devoted to screening to reduce the risks
of congenital toxoplasmosis [2±5]. Acquisition of
toxoplasma infection outside pregnancy is rarely
considered to be a public health problem.
The bene®ts of prenatal or postnatal screening for
congenital toxoplasmosis depend on the risk of
symptoms in the absence of screening and the
eﬀectiveness of treatment in reducing this risk. In
* Author for correspondence.
symptomatic patients, congenital toxoplasmosis most
commonly causes ocular symptoms manifest as
episodes of transient visual loss and pain during child
and adulthood due to reactivation of latent cysts and
the formation of new retinochoroidal lesions. Aﬀected
individuals may also present with signs or symptoms
of permanent visual impairment due to lesions arising
within the macular vascular arcade. In ®ve prospective
cohort studies [1a, 2, 6±8] 29}102 (28%) congenitally
infected children developed retinochoroidal lesions,
but in 4 of these follow-up was limited to 1±6 years of
age. In one study, 11 congenitally infected individuals
were examined at 20 years of age and retinochoroidal284 R. E. Gilbert and others
lesions were detected in 9 (82%), in 7 of these before
7 years of age [6].
Toxoplasma retinochoroidal lesions are considered
to originate from congenital infection except where
there is clear evidence of acquired toxoplasmosis
[9±12]. This view is diﬃcult to challenge as serological
evidence to date infection as congenital or postnatally
acquired is rarely available. Nevertheless, the pattern
of ocular disease described in cohort studies of
congenitally infected children diﬀers from that seen by
ophthalmologists. Most patients present aged 10±40
years with acute onset of pain and visual impairment
lasting 6±8 weeks [13, 14] due to reactivation of latent
toxoplasma cysts.
In Britain, screening for congenital toxoplasmosis is
not routinely oﬀered due to the lack of information on
the burden of preventable disease [15]. The aim of this
study was to estimate the lifetime risk and describe the
clinical severity of symptoms associated with retino-
choroidal lesions in an unscreened, British-born
population. Secondly, we assessed variation in the
incidence of symptoms by country of birth and ethnic
group in order to identify high risk groups. Lastly, we
compared the age at onset of symptoms in our
patients with that reported in cohort studies of
congenitally infected children. We established a
population-based, active reporting scheme among
ophthalmologists serving a population of 7±4 million
to ascertain patients presenting with any symptoms
suspected to be due to toxoplasma infection.
METHOD
Reporting scheme
An `active' monthly reporting scheme was established
among 25 ophthalmology units serving 39 districts in
4 areas of England: south Greater London (12
districts, population 2574000), North East Greater
and outer metropolitan London (14 districts, popu-
lation 1973000 and 9 districts, population 1012000
respectively), Leicester metropolitan district (1 dis-
trict, population 266000), and Birmingham (3
districts, population 1435000). Two ophthalmology
units sited outside the four regions were used to detect
patient drift.
Ineach unit the ophthalmologist who wouldusually
see patients with toxoplasma retinochoroiditis re-
ceived a monthly card asking whether or not any cases
of suspected symptomatic toxoplasma eye disease had
been seen in the unit within the previous month.
Eﬀorts to improve ascertainment included placing
study information packs in each outpatient and
casualty department to remind staﬀ to refer all
suspected cases, publicising the study at local oph-
thalmology meetings, sending a newsletter to all units,
and sending reminders by post and telephone if cards
were not returned.
The scheme operated over 18 months from January
1994 to July 1995 and involved 19 reporting ophthal-
mologists in 25 units (due to local referral patterns, 3
ophthalmologists reported cases for several units).
Sixteen of 19 ophthalmologists returned at least 80%
of the monthly report cards, two reported patients
retrospectively and one never responded. Five
ophthalmologists reported no patients during the
study period.
Data collection
For each case,the reporting ophthalmologist recorded
age, postcode, country of birth and ethnic group
(using the 1991 census terms), clinical presentation
and signs, and dates at similar previous episodes.
They were also asked to attribute each patient's
®ndings to toxoplasmosis as follows: de®nite (retinitis
with cells present in vitreous in association with one or
more pigmented retinochoroid scars in the same eye);
probable (retinitis with cells present in vitreous with
one or more pigmented retinochoroid scars in the
contralateral eye); and possible (severe vitritis ob-
scuring retinal detail but retinal in¯ammation or scar
identi®able).
Serum samples were analysed centrally for toxo-
plasma-speci®c antibodies using the EIKEN aggluti-
nation test [16] and ISAGA for speci®c IgM [17]. All
IgM positive samples, EIKEN and ISAGA negative
samples and an unselected sample of others were sent
for con®rmatory testing using the dye test and ISAGA
IgM test at the Regional Reference Laboratory (St
George's Hospital Medical School, London).
Incidence estimates were derived using patients
resident within the study area as the numerator and
residents of all ages according to country of birth and
ethnic group for each district as the denominator
(obtained from the National Census, 1991 local base
statistics, Oﬃce for Population Censuses and
Surveys). The annual incidence of all symptomatic
episodes, whether ®rst or repeat, re¯ects overall
morbidity due to the risk of the disease and risk of
recurrence. However, the risk of ever having symp-
tomatic toxoplasma retinochoroiditis (lifetime risk) is285 Symptomatic toxoplasma eye disease
also important to individuals. Lifetime risk was
calculated from the cumulative lifetime risk of
symptoms by age 60 years [18] based on patients
presenting with a ®rst symptomatic episode as
inclusion of repeat episodes would have introduced
referral bias. This estimation was limited to patients
born in Britain or West Africa due to small numbers
in other ethnic groups.
RESULTS
A total of 112 patients was reported during the study
period of whom 103 ful®lled the criteria of symp-
tomatic eye disease suspected to be due to toxoplasma
infection. Of the 9 excluded, 2 had been detected by
optometrists during routine eye examination for
refractory errors and were asymptomatic (i.e. no
visualimpairmentoracutesymptomsofreactivation);
3 had serum samples taken but no clinical data (1 was
the mother of an aﬀected person); 2 children reviewed
forcongenitaltoxoplasmosishad no detectable retino-
choroiditis; and 1 adult and 1 child reviewed for
permanent visual impairment had no new symptoms
during the study period.
The103patientreportsincluded16patientsresident
outside the study area. Results are reported on 87
episodes in 84 patients resident within the study area
(3 had a repeat symptomatic episode during the 18
month study period). Forty-one of 84 patients were
male.
Diagnostic certainty
Clinical assessment was the sole basis for determining
whether eye signs were due to toxoplasma infection,
and in the majority of cases (71}87, 82%), this
judgement was reported before serology results were
available. Ophthalmologists' attribution of ®ndings to
toxoplasma infection were: de®nite in 69}87 (79%),
probable in 14}87 (16%), possible in 3 and in 1 case
the likelihood of toxoplasma infection was not stated.
Antibodies were not detected by the EIKEN, Dye
(!2I U }ml) or ISAGA tests in 3 patients (1 probable,
1 possible and 1 not stated to be due to toxoplasma
infection) and serum specimens were not obtained
from 5 patients.
Clinical characteristics
Mean age at presentation for all 87 episodes was 31±1
years. For patients presenting with a ®rst episode (n¯

























































































Fig. 1. Age at presentation for all patient episodes (n¯87)
and for patients reporting no previous episode (n¯41).
similar for patients born in Britain or West Africa:
25±7 years (n¯24) and 29±7( n¯10) respectively.
Presenting symptoms were acute visual impairment
in 80 (92%) episodes and pain in 30 (34%). No
patient was identi®ed for the ®rst time with chronic
visual impairment or reported to be immunocom-
promised. In 55}87 (63%) episodes lesions involved
theposteriorpole,4ofwhichwerebilateral.Unilateral
visual acuity was 6}60 or less in 18 (21%) episodes
and in 7 (8%) bilateral visual acuity was 6}12 or less,
which disquali®es patients from driving. Visual acuity
was the same or improved in all 3 patients seen during
a repeat episode, only 1 of whom had been treated
during the ®rst episode. There was no evidence of a
diﬀerence in site of lesions or visual acuity according
to country of birth or ethnic group, but these
comparisons involve small numbers. Systemic treat-
ment (antibiotics, steroids or both) was prescribed for
43}87 episodes, 35 (81%) of which involved active
retinochoroidal lesions at the posterior pole (i.e.
within the macular vascular arcade).
Two patients, both born in Britain, had evidence of
congenital infection. One presented with a painful red
eye at 2±9 years, having been blind since birth (best eye
6}60) due to bilateral posterior pole lesions. Toxo-
plasma-speci®c IgM antibodies, intracranial bleeding
and liver disease were present at age 1 month. The
second presented with acute visual loss at 34 years,
having had a similar episode at 13 years. She had been
treated for amblyopia and retinal detachment in early
childhood (assumed to be due to toxoplasma retino-
choroiditis), had unilateral posterior pole lesions and
no neurological symptoms.
Five patients (all aged 29 years or older) had
toxoplasma-speci®c IgM antibodies and no history of286 R. E. Gilbert and others
Table 1. Incidence of symptomatic toxoplasma retinochoroiditis according to country of birth and ethnic group










All All 87 7423 0±8( 0 ±6±1±0)
Britain All 45 6652 0±4( 0 ±3±0±6)
Britain White 29 5674 0±3( 0 ±2±0±7)
Britain Black 10 266 2±5( 1 ±2±4±6)
Britain Other 6 712 0±6( 0 ±2±1±2)
W. Africa Black 24 55 29±3 (18±8±43±6)
E. Africa Black 2 9 14±7( 1 ±8±53±1)
W. Indies Black 6 139 2±9( 1 ±0±6±3)
Indian Sub Continent All 0 254 (0±0±8)
Europe (not Britain) All 4 334 0±8( 0 ±2±2±0)
Rest}unknown All 6
Table 2. Cumulative lifetime risk of symptomatic toxoplasma retinochoroiditis for people born in Britain and
West Africa based on ®rst observed episode



















0±4 1 1 0±70 0 0
5±15 3 3 2±90 0 0
16±19 4 4 6±6 2 2 175±4
20±29 17 9 12±5 6 2 238±9
30±44 14 5 16±1 16 6 381±8
45±59 6 2 18±0 0 0 381±8
Total 45 24 18±0 24 10 381±8
signs or symptoms in early childhood. Three reported
episodes with similar symptoms 14 years, 4 years, and
7 months previously. Four out of ®ve patients had old
scars as well as an active lesion.
Incidence rate
The overall incidence of 0±8 episodes}100000 per year
diﬀered substantially according to country of birth
and ethnic group (Table 1). Of the 87 episodes, 45
(52%) occurred in patients born in Britain, giving an
incidence of symptomatic toxoplasma retinochoroid-
itis of 0±45 per 100000 per year (95% CI: 0±33±0±60).
There was a tenfold higher incidence in black
compared with white people born in Britain and the
rate in black people born in West Africa was tenfold
higher than for black people born in Britain. The
latter had a similar rate to black people born in the
West Indies. Only two black East Africans were
identi®ed giving a high incidence rate for this group
but with wide con®dence intervals. No patients born
in the Indian subcontinent were identi®ed, despite a
large denominator population.
Lifetime risk
The cumulative risk of symptomatic retinochoroiditis
was calculated from the age speci®c incidence for the
®rst symptomatic episode which occurred during the
study period (Table 2). For people born in Britain, the
estimated risk by age 60 years was 18 per 100000
liveborns (95% CI: 10±8±25±2). Black people born in
West Africa had a 20-fold higher lifetime risk
(382}100000 population; 95% CI: 99±664) compared
with people of any ethnicity born in Britain.
DISCUSSION
In our study population, symptoms of toxoplasma
retinochoroiditis were mild and, for people born in
Britain, 18 in every 100000 would eventually develop287 Symptomatic toxoplasma eye disease
symptoms, mainly in adulthood. Black people (par-
ticularly those born in West Africa) were aﬀected
more commonly than white. What implications do
these ®ndings have for public health?
The introduction of a new screening programme
should require the demonstration of an important
health problem which can be prevented by early
detection and treatment [19]. We estimated a low
burden of ocular disease. If the lifetime risk were
extrapolated to the 700000 births in Britain each year,
an estimated 75±178 individuals would eventually
develop symptoms requiring ophthalmological at-
tention at a mean age of 26 years; 8% would have
bilateral visual impairment suﬃcient to disqualify
them from driving although this would be likely to be
transient in most cases [13]. How much reduction in
disease might be achieved by early detection and
treatment is not known, as no controlled studies have
been published on the eﬀect of prenatal or infant
treatment on the development of retinochoroiditis.
Even if all symptomatic retinochoroiditis were due to
congenital toxoplasmosis, the low risk and mild
symptoms in an unscreened British population in-
dicate limited potential bene®ts for prenatal or
postnatal screening.
Error in our estimates may have arisen for several
reasons. Firstly, our ®ndings largely re¯ect the
experience of individuals born 20±40 years ago. Since
then, the incidence of toxoplasma infection in adults,
and presumably of congenital toxoplasmosis, has
fallen approximately twofold [20]. Secondly, we
included three seronegative patients. Although similar
cases have been reported [6, 8], they may have been
misdiagnosed leading to an overestimate of the risk of
toxoplasma eye disease. Thirdly, we have assumed
that the risk of disease observed in British-born
individuals living mainly in urban Greater London,
the West Midlands or Leicester, was the same across
the rest of Britain. Data on regional variation in
symptomatic toxoplasma eye disease in Britain are
lacking. An urban±rural gradient in the prevalence of
toxoplasma IgG in British-born individuals has been
reported in one study in South East England [21] but
not con®rmed by a study in East England [22].
Fourthly, we may have underestimated the risk of
symptomatic eye disease due to underascertainment
of cases although the `active' reporting method has
achieved high ascertainment rates for other disorders
[23]. Failure to refer patients to an ophthalmologist
who are initially identi®ed in a casualty department,
by an optician or a general practitioner is unlikely, but
some clinicians may have failed to suspect the
condition. However, the study missed individuals who
did not seek medical care and excluded patients with
permanent visual impairment who did not develop
symptoms during the study period. We determined
the frequency of patients with permanent visual
impairment by reviewing all ophthalmological case
notes of patients with suspected toxoplasmosis over 2
years at the tertiary referral centre for children
(1994±6, Great Ormond Street Hospital for Children)
and the tertiary referral unit for ophthalmology
(1992±4, Moor®eld's Eye Hospital). One of nine
children in the study area at the former and 1}70
patients at the latter were under review during the
study period for permanent visual impairment and
had no history of symptoms of acute in¯ammation.
Evidencefromcause-speci®cstudiesofchildrenfailing
vision screening [24] and from blind registrations [25]
further supports clinicians' perceptions that patients
with permanent visual impairment without episodes
of acute in¯ammation are rare.
Decisions about screening need to take account of
non-ocular symptoms due to congenital toxo-
plasmosis, although data are limited due to small
numbers aﬀected and lack of long-term follow up.
Mental retardation or abnormal motor development
was reported in 3 of the 102 congenitally infected
children in 5 prospective cohort studies births
[1a, 2, 6±8]. Only one study compared intellectual
development in infected and uninfected children and
reported no diﬀerence in school performance at age 7
years [6]. Reports of more frequent adverse develop-
mental outcome may be due to selective recruitment
of symptomatic children [26]. In Britain, a surveillance
study based on all births in 1989}90 (approx. 700000)
detected 14 severely aﬀected congenitally infected
oﬀspring, some of whom were stillborn and some had
no involvement of the central nervous system [27].
At the present time, public health programmes are
largely focused on congenital toxoplasmosis. We
found evidence of congenital infection in only 2}84
patients and no others presented with, or reported
having had similar symptoms before 10 years of age.
This contrasts with the high incidence of lesions
(29}102, 28%) detected in cohort studies of con-
genitally infected children, in 27 before 7 years of age.
Unilateralvisualimpairmentormacularlesions(likely
to result in permanent visual impairment) were noted
in half (14}29) of these children.
These contrasting clinical patterns suggest diﬀerent
aetiologies and a role for postnatally acquired in-288 R. E. Gilbert and others
fection in a proportion of our patients. However,
conclusive evidence of acquired disease was lacking.
Five adult patients had speci®c IgM antibodies, of
whom three reported similar symptoms 14 years, 4
years and 7 months previously. Persistence or re-
surgence of IgM antibodies has rarely been reported
in congenital infection [28] but occurs in about 5% of
postnatally acquired infection [12]. Hence presence of
IgM in adults is more likely to re¯ect recent or old
postnatally acquired infection but does not rule out
congenital infection.
There were no ®ndings to favour an acquired or
congenital aetiology in the remaining 77 patients.
Calculation of the expected risks of retinochoroiditis
attributable to congenital or acquired infection,
produces broad and uncertain estimates due to the
paucity of published data. Recent cohort studies in
northern Europe and north America give ®gures for
the birth prevalence of congenital toxoplasmosis
ranging from 0±8t o5 }10000 live births [1a, 2, 6±8]. If
we apply these rates to the British-born population
and assume that 80% of children develop lesions by
adulthood [6], 6±40}100000 people would develop
retinochoroidal lesions due to congenital toxoplas-
mosis. Approximately 13% of the British-born
population aged 60 years in the regions studied have
acquired toxoplasmosis postnatally (based on age
speci®c seroprevalence rates for British people born in
1988±90 [29]). Burnet and colleagues [30] reported
that 0±3±0±7% people with toxoplasma infection
acquired during an outbreak in Vancouver presented
with symptoms to ophthalmologists. If the same risks
applied to Britain, between 39 and 91 per 100000
people aged 60 and under (13% times 0±3±0±7%)
would have symptoms due to acquired toxoplasma
retinochoroiditis, well in excess of our estimated
lifetime risk of 18}100000. This discrepancy may be
due to underestimation of the denominator in Van-
couver,ahigherprevalenceofsymptoms(possiblydue
to excessive organism load or virulence), and diﬀerent
thresholds for ophthalmological consultation. How-
ever, until further research generates more robust
estimates, these limited data suggest that retino-
choroidal lesions due to acquired toxoplasmosis are at
least as common as those due to congenital infection.
The high incidence of symptomatic toxoplasma
retinochoroiditis in black people born in West Africa
con®rms ®ndings of a smaller study [25] and has been
noted previously [31±33]. Possible explanations in-
clude a high incidence of congenital or postnatally
acquired infection, increased susceptibility to the
development of symptomatic lesions, possibly due to
diﬀerences in strain or organism load (through
acquisition of tissue cysts rather than oocysts), or
genetic susceptibility to disease. Our study predicts
that more than 1 in 300 West Africans will be aﬀected.
These ®ndings require con®rmation in West African
settings and further studies to relate acquisition of
infection to preventable risk factors. Exposure to
Toxoplasma gondii, commonly by ingestion of in-
fected, undercooked meat and oocyst contaminated
soil, may be reduced by primary prevention measures
and warrants public health attention.
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